Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TAKHZYRO DIN 02566257

Status: Approved
Holder: TAKEDA CANADA INC
Molecule: LANADELUMAB

Health Canada record

Active ingredient(s)LANADELUMAB 150 MG
Dosage formSolution
RouteSubcutaneous
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCB06AC05 LANADELUMAB
Original market date
Current status date02-Mar-2026
SourceHealth Canada DPD

Establishment licence of the holder

Takeda Canada Inc. — licence 101769, currently licensed, last inspection rating C (2026-02-24).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing LANADELUMAB

DINProductCompanyFormStrengthStatus
02480948TAKHZYROTAKEDA CANADA INCSolutionLANADELUMAB 300 MGMarketed
02505614TAKHZYROTAKEDA CANADA INCSolutionLANADELUMAB 300 MGMarketed
02564483TAKHZYROTAKEDA CANADA INCSolutionLANADELUMAB 300 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
370762026-03-02Supplement to a New Drug Submission (SNDS)Expansion of the indication and addition of a strength: TAKHZYRO (lanadelumab injection) is indicated for: • routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 2 years and older. TAKHZYRO is not intended for acute treatment of HAE attacks
Request a quote for TAKHZYRO

How to read a Canadian DIN record